Literature DB >> 12683513

A cluster of primary varicella cases among healthcare workers with false-positive varicella zoster virus titers.

Amy Behrman1, D Scott Schmid, Anne Crivaro, Barbara Watson.   

Abstract

BACKGROUND: Five cases of primary varicella zoster virus (VZV) we re diagnosed among hospital healthcare workers (HCWs). All had complied with a pre-employment VZV screening program and had been considered immune.
OBJECTIVES: To summarize the investigation of VZV among un-immunized HCWs and to provide recommendations for avoiding false-positive serologic tests.
DESIGN: Risk of transmission of VZV to susceptible HCWs is minimized through serologic screening. Varicella vaccine is recommended for susceptible HCWs. A commercially available latex bead agglutination assay (LA) is widely used because it is rapid and easy to perform. LA was compared with the whole-cell varicella ELISA standardized in the Centers for Disease Control and Prevention (CDC) National Herpes Laboratory. SETTING/POPULATION: Large inner-city, tertiary-employee population.
RESULTS: In a year, 5 HCWs presented with laboratory-confirmed primary varicella infection. Four had VZV exposures 2 weeks prior to presentation. All had documented positive VZV titers by LA performed at hire. None were offered VZV vaccination. The original LAs were judged false-positives. INTERVENTION/FOLLOW-UP INVESTIGATION: Fifty-three consecutive VZV LA samples from the hospital laboratory were retested at the CDC. Forty-four samples concurred. Of the remaining 9, 4 were positive by hospital LA but negative by CDC IgG ELISA. Four were equivocal by hospital LA but negative by CDC IgG ELISA and LA. One was positive by hospital LA but negative by LA and equivocal by ELISA at the CDC.
CONCLUSION: LA may be prone to false-positive results and inappropriate for screening hospital HCWs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12683513     DOI: 10.1086/502187

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  5 in total

1.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

2.  Comparative study of the standard fluorescent antibody to membrane antigen (FAMA) assay and a flow cytometry-adapted FAMA assay to assess immunity to varicella-zoster virus.

Authors:  M M Lafer; L Y Weckx; M I de Moraes-Pinto; A Garretson; S P Steinberg; A A Gershon; P S LaRussa
Journal:  Clin Vaccine Immunol       Date:  2011-05-25

3.  A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens.

Authors:  Maria G Vizoso Pinto; Klaus-Ingmar Pfrepper; Tobias Janke; Christina Noelting; Michaela Sander; Angelika Lueking; Juergen Haas; Hans Nitschko; Gundula Jaeger; Armin Baiker
Journal:  Virol J       Date:  2010-07-20       Impact factor: 4.099

4.  Validity of self-reported varicella disease history in pregnant women attending prenatal clinics.

Authors:  Barbara Watson; Rachel Civen; Meredith Reynolds; Karl Heath; Dana Perella; Tina Carbajal; Laurene Mascola; Aisha Jumaan; Laura Zimmerman; Abike James; Carlene Quashi; Scott Schmid
Journal:  Public Health Rep       Date:  2007 Jul-Aug       Impact factor: 2.792

5.  Evaluation of the Tetracore Orthopox BioThreat® antigen detection assay using laboratory grown orthopoxviruses and rash illness clinical specimens.

Authors:  Michael B Townsend; Adam MacNeil; Mary G Reynolds; Christine M Hughes; Victoria A Olson; Inger K Damon; Kevin L Karem
Journal:  J Virol Methods       Date:  2012-09-05       Impact factor: 2.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.